Independent Advisor Alliance Sells 4,153 Shares of AbbVie Inc. $ABBV

Independent Advisor Alliance reduced its position in AbbVie Inc. (NYSE:ABBV) by 3.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,718 shares of the company’s stock after selling 4,153 shares during the period. AbbVie accounts for about 0.6% of Independent Advisor Alliance’s portfolio, making the stock its 22nd largest position. Independent Advisor Alliance’s holdings in AbbVie were worth $25,755,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. World Investment Advisors boosted its holdings in shares of AbbVie by 12.0% in the 4th quarter. World Investment Advisors now owns 127,623 shares of the company’s stock valued at $26,592,000 after buying an additional 13,698 shares in the last quarter. Topsail Wealth Management LLC boosted its holdings in shares of AbbVie by 63.6% in the 4th quarter. Topsail Wealth Management LLC now owns 4,585 shares of the company’s stock valued at $1,048,000 after buying an additional 1,783 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of AbbVie by 10.9% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 325,111 shares of the company’s stock valued at $74,285,000 after buying an additional 32,000 shares in the last quarter. Northeast Investment Management boosted its holdings in shares of AbbVie by 5.9% in the 4th quarter. Northeast Investment Management now owns 12,211 shares of the company’s stock valued at $2,790,000 after buying an additional 685 shares in the last quarter. Finally, Argos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 4th quarter valued at about $395,000. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ABBV shares. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Canaccord Genuity Group lifted their target price on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.90.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Evercore ISI recently raised its price target on AbbVie to $236 from $232 and kept an Outperform rating, reinforcing the bullish analyst tone around the shares. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
• Positive Sentiment: AbbVie’s full-year 2026 adjusted EPS guidance of $14.37 to $14.57 appears to be supporting confidence that earnings can remain durable even as the company transitions beyond Humira. AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment
• Positive Sentiment: Recent articles highlighting strong long-term growth potential, rising dividends, and improving drug portfolio sentiment are helping position ABBV as a defensive healthcare name with income appeal. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
• Neutral Sentiment: At the 2026 Annual Meeting, shareholders elected directors and maintained AbbVie’s governance structure; this is supportive of continuity, but not likely a major stock-moving catalyst on its own. AbbVie Shareholders Back Directors, Maintain Governance Structure
• Neutral Sentiment: Several recent writeups argue that AbbVie’s growth engine is “firing on all cylinders,” largely due to SKYRIZI and RINVOQ, but these are more confirmation of the current narrative than a fresh catalyst. AbbVie’s Growth Engine Is Firing On All Cylinders
• Negative Sentiment: Some commentary remains cautious, noting that AbbVie has lagged the broader market over the past year and still faces pressure from competition and investor skepticism around its longer-term multiple. AbbVie Stock: Is Wall Street Bullish or Bearish?
• Negative Sentiment: News that a smaller biotech beat one of AbbVie’s major drug programs is a reminder that competitive risks remain in key therapeutic areas. A Tiny Biotech Just Beat AbbVie’s $17 Billion Drug. Should Investors Be Worried?

AbbVie Trading Up 2.5%

ABBV opened at $207.83 on Wednesday. AbbVie Inc. has a 12-month low of $176.57 and a 12-month high of $244.81. The firm has a market capitalization of $367.20 billion, a PE ratio of 102.38, a P/E/G ratio of 0.70 and a beta of 0.32. The firm has a 50 day moving average of $211.75 and a two-hundred day moving average of $220.44.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.46 EPS. As a group, analysts predict that AbbVie Inc. will post 14.32 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 340.89%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.